Skip to main content
Clinical Trials/jRCT2041250143
jRCT2041250143
Recruiting
Not Applicable

A PHASE IIb, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY WITH AN ACTIVE TREATMENT EXTENSION TO ASSESS THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF RO7837195 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Not provided0 sites17 target enrollmentStarted: TBD

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
17

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized

Eligibility Criteria

Ages
18age old over to No limit (—)
Sex
All

Inclusion Criteria

  • Diagnosis of ulcerative colitis (UC) established at least 3 months
  • Moderately to severely active UC assessed by mMS
  • Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC

Exclusion Criteria

  • Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
  • Diagnosis of Crohn's disease or indeterminate colitis
  • Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a)
  • Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12 and/or IL-23

Investigators

Sponsor
Not provided

Similar Trials